5 Key Takeaways
-
1
The FDA approved Amneal's prednisolone acetate ophthalmic suspension, USP 1%, for treating steroid-responsive ocular inflammation.
-
2
Prednisolone acetate ophthalmic suspension is a sterile, topical anti-inflammatory agent for ophthalmic use.
-
3
The product references Pred Forte, a trademark of Allergan, Inc., an AbbVie company.
-
4
Amneal plans to launch the prednisolone acetate ophthalmic suspension in the third quarter of 2025.
-
5
Common adverse reactions include elevated intraocular pressure, potential glaucoma, optic nerve damage, and delayed wound healing.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.